Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Launching SCEMBLIX®, a novel STAMP inhibitor with
potential to transform the standard of care in CML
• SCEMBLIX®
(asciminib) 20 mg. 40 mg tablets
Strong clinical profile addressing sizable
medical need
Superior clinical profile to bosutinib in late line
CML1 with early 2x improvement in MMR and
>3x fewer discontinuations due to AEs
Clinically meaningful efficacy in patients with
T3151 CML-CP
~25% of all CML patients addressable with
current label
Potential to provide another treatment option in
1L CML; Ph3 pivotal trial ongoing (filing in 2025)
US launch excellence building on CML
experience
Executing with excellence, leveraging
decades of CML experience
Patient assistance program in place with
more than 50 patients registered; over 150
enrollments in managed access program
Already included in NCCN guidelines;
strong medical engagement with
>50 US centers in clinical trials
HCPs able to secure access for patients,
while formulary listings are ongoing
STAMP - Specifically Targeting the ABL Myristoyl Pocket. 1. Rea D et al, Blood 2021 Nov 25;138(21).
36 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation